MiMedx Group, Inc. (NASDAQ:MDXG) Given Average Rating of “Buy” by Brokerages

Shares of MiMedx Group, Inc. (NASDAQ:MDXG) have received an average rating of “Buy” from the five ratings firms that are covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have covered the stock in the last year is $12.00.

A number of research firms have commented on MDXG. Craig Hallum decreased their target price on shares of MiMedx Group from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $11.00 target price on shares of MiMedx Group in a research report on Thursday, August 1st. Finally, StockNews.com cut shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday.

Institutional Trading of MiMedx Group

Hedge funds have recently made changes to their positions in the business. Caxton Associates LP acquired a new stake in shares of MiMedx Group during the first quarter worth about $1,018,000. Victory Capital Management Inc. increased its stake in shares of MiMedx Group by 909.0% during the second quarter. Victory Capital Management Inc. now owns 138,449 shares of the company’s stock worth $959,000 after buying an additional 124,727 shares during the period. Isthmus Partners LLC increased its stake in shares of MiMedx Group by 30.4% during the second quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock worth $27,000 after buying an additional 91,714 shares during the period. Harbor Capital Advisors Inc. increased its stake in shares of MiMedx Group by 299.9% during the third quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company’s stock worth $6,074,000 after buying an additional 770,744 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of MiMedx Group by 13.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 32,978 shares of the company’s stock worth $254,000 after buying an additional 3,806 shares during the period. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Trading Up 1.5 %

Shares of MDXG stock opened at $7.64 on Tuesday. The company’s 50-day moving average price is $6.14 and its 200-day moving average price is $6.72. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of 13.89 and a beta of 1.94. MiMedx Group has a twelve month low of $5.47 and a twelve month high of $9.27.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.